Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

The effect of SYX-5219 on an immune response in the skin.

This research study is testing a new medicine, SYX-5219, in people who have eczema, also known as atopic dermatitis. Eczema is a common skin condition that makes your skin red, itchy, and inflamed. The main goal of this study is to find out how SYX-5219 works inside your body, specifically focusing on how it affects the immune system in your skin. The immune system is your body's defence against illness, but in eczema, it can sometimes overreact and cause skin problems. By studying this, researchers hope to learn if SYX-5219 could be a helpful treatment for eczema in the future. This is an early stage study, so it's mainly about understanding the medicine better.

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Sitryx Therapeutics Limited

Enrolment target

Start

14 Nov 2025

Atopic dermatitis (AD)

What is this study about?

This study is called an early-stage clinical trial. This means it's one of the first times this new medicine, SYX-5219, is being given to people. The main purpose at this stage is to understand how the medicine behaves in the human body, especially how it interacts with the skin's immune system in people who have eczema. Think of your immune system as your body's shield; sometimes it can get a bit overactive and cause conditions like eczema.

Eczema, also known as atopic dermatitis, is a common skin condition that can make your skin very itchy, dry, and inflamed. It can be uncomfortable and sometimes affect daily life. Researchers hope that by understanding how SYX-5219 affects the immune system in the skin, they can learn if it has the potential to calm down the overactive responses that cause eczema symptoms.

Taking part in studies like this is really important because it helps scientists learn more about new medicines. This knowledge is crucial for developing better treatments for conditions like eczema in the future. While this study isn't directly looking to cure eczema right now, the information gathered will help in designing future studies that might lead to new and effective treatments.

Key takeaways

This is an early-stage study for a new eczema medicine.
It aims to understand how SYX-5219 affects the skin's immune system.
Open to adults aged 18 and over, both men and women.
Participation involves clinic visits, taking medicine, and health checks.
You'll learn about potential risks and benefits before deciding to join.
Your involvement helps advance future treatments for eczema.

Who may be eligible?

To join this study, you need to be at least 18 years old. There's no upper age limit, so people of all adult ages can be considered. The study is open to both men and women.

More detailed checks will be done by the study team to make sure it's safe and appropriate for you to participate. This might include reviewing your medical history and current health. It's important that you don't have any other serious health conditions that could affect the study's results or your safety.

The study team will explain everything clearly and answer any questions you have. They need to be sure that the study is a good fit for you and that you understand what's involved before you decide to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have eczema (atopic dermatitis)?
Are you able to attend appointments regularly at the study clinic?
Are you free from other serious health conditions that might interfere?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you'll be given the new medicine, SYX-5219, as instructed by the study team. You'll have several visits to the study clinic where doctors and nurses will monitor your health and how your body is reacting to the medicine. These visits will involve various assessments, which might include blood tests, skin checks, and questions about how you're feeling.

The total duration of your involvement in the study will be explained in detail by the research team. This includes the time you'll be taking the medicine, as well as any follow-up visits after you've finished the treatment. Before you start, you'll receive a detailed schedule outlining all appointments and procedures. You will always be fully informed about what to expect at each stage.

Potential risks and benefits

Participating in research studies can offer the potential to contribute to medical science and potentially help others in the future by advancing knowledge about eczema treatments. While this study is mainly about understanding the medicine, very early studies sometimes offer potential direct benefits. However, as with any new medicine, there might be side effects or risks that aren't yet fully known. The study team will carefully explain all potential risks and discomforts. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is eczema?

Eczema (or atopic dermatitis) is a common skin condition that makes your skin red, dry, and very itchy.

What is SYX-5219?

SYX-5219 is a new medicine being tested in this study to see how it affects the immune system in the skin for people with eczema.

How long does the study last?

The exact length of time you'd be involved will be fully explained by the study team before you decide to join.

Will I get paid for taking part?

It's common for studies to cover travel costs, but you should ask the study team about any potential reimbursement for your time.

Can I leave the study if I change my mind?

Yes, you can choose to leave the study at any point, and it won't affect your regular medical care.